Tyk2 Overview
Molecule Name
Tyrosine-protein kinase 2
Synonyms
Tyk2,tyrosine kinase 2
Drug Development Progress
Drugs in Clinical Trials43
Approved Drugs4
Highest Development StageApproved
Target Synonym
EC:2.7.10.2，TYK2，Tyrosine Kinase 2，Non-Receptor Tyrosine-Protein Kinase TYK2，EC 2.7.10.2，IMD35，JTK1，TYK2 Kinase，EC 2.7.10
Background
Tyk2 was the first member of the JAK family that was described (the other members are JAK1, JAK2, and JAK3). It has been implicated in IFN-α, IL-6, IL-10 and IL-12 signaling. Tyk2 functions primarily in IL-12 and type I-IFN signaling. Tyk2 deficiency has more dramatic effects in human cells than in mouse cells. However, in addition to IFN-α and -β and IL-12 signaling, Tyk2 has major effects on the transduction of IL-23, IL-10, and IL-6 signals. Recently, it has been recognized that IL-12 and IL-23 share ligand and receptor subunits that activate Tyk2. Tyk2 is activated by IL-10, and its deficiency affects the ability to generate and respond to IL-10.
Tyk2 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| TLL-018 | TLL-018 | Phase 3 Clinical | Tll Pharmaceutical Llc | Arthritis, Rheumatoid; Chronic Urticaria; Colitis, Ulcerative; Dermatitis, Atopic; Lupus Erythematosus, Systemic; Plaque psoriasis; Psoriasis; Urticaria | Details |
| CMS-D001 | CMS-D001 | Phase 3 Clinical | China Medical System Holdings Ltd | Autoimmune Diseases; Dermatitis, Atopic; Plaque psoriasis; Psoriasis | Details |
| WD-890 | WD-890; WD890 | Phase 3 Clinical | Ningbo Wenda Pharma | Lupus Erythematosus, Systemic; Plaque psoriasis; Psoriasis | Details |
| BHV-8000 | TLL-041; TLL041 | Phase 3 Clinical | Hangzhou Highlightll Pharmaceutical Co Ltd | Alzheimer Disease; Amyotrophic Lateral Sclerosis; Central Nervous System Diseases; Parkinson Disease | Details |
| Velzatinib | M-4205; IDRX-42; GSK-6042981 | Phase 3 Clinical | IDRx Inc | Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors | Details |
| Envudeucitinib | ESK-001; FTP-637 | Phase 3 Clinical | Haisco Pharmaceutical Group Co Ltd | Autoimmune Diseases; Hepatic Insufficiency; Lupus Erythematosus, Systemic; Panuveitis; Plaque psoriasis; Psoriasis; Renal Insufficiency; Uveitis, Intermediate; Uveitis, Posterior | Details |
| D-2570 | D-2570; D2570 | Phase 3 Clinical | Inventisbio Co Ltd | Arthritis, Psoriatic; Autoimmune Diseases; Colitis, Ulcerative; Lupus Erythematosus, Systemic; Plaque psoriasis; Psoriasis | Details |
| VVN-461 | VVN461LD; VVN-461; VVN461e; VVN-461-e | Phase 3 Clinical | VivaVision Biotech Inc | Dry Eye Syndromes; Inflammation; Postoperative inflammation; Uveitis; Uveitis, Anterior | Details |
| Zasocitinib | NDI-034858; TAK-279 | Phase 3 Clinical | Nimbus Therapeutics LLC | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Erythrodermic psoriasis; Generalised pustular psoriasis; Hidradenitis Suppurativa; Plaque psoriasis; Psoriasis; Vitiligo | Details |
| Quecitinib | QY201; QY-201 | Phase 3 Clinical | E-nitiate Biopharmaceuticals (Hangzhou) Co Ltd | Alopecia Areata; Arthritis, Rheumatoid; Dermatitis, Atopic; Prurigo; Prurigo Nodularis; Psoriasis; Spondylitis, Ankylosing; Vitiligo | Details |
| ICP-488 | ICP-488 | Phase 3 Clinical | InnoCare Pharma Ltd | Autoimmune Diseases; Lupus Erythematosus, Cutaneous; Plaque psoriasis; Psoriasis | Details |
| HS-10374 | HS-10374; hs 10374; hs10374; hs-10374 | Phase 3 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Alopecia Areata; Arthritis, Psoriatic; Plaque psoriasis; Psoriasis | Details |
| Soficitinib | ICP-332 | Phase 3 Clinical | InnoCare Pharma Ltd | Chronic Urticaria; Dermatitis, Atopic; Plaque psoriasis; Prurigo Nodularis; Psoriasis; Urticaria; Vitiligo | Details |
| SYHX-1901 | SYHX-1901 | Phase 3 Clinical | Cspc Ouyi Pharmaceutical Co Ltd | Alopecia Areata; Arthritis, Rheumatoid; Dermatitis, Atopic; Drug-Related Side Effects and Adverse Reactions; Hematologic Neoplasms; Lupus Erythematosus, Systemic; Plaque psoriasis; Psoriasis; Solid tumours; Vitiligo | Details |
| WXSH-0150 | WXSH-0150; TUL-01101 | Phase 2 Clinical | Zhuhai United Laboratories Co Ltd | Arthritis, Rheumatoid; Dermatitis, Atopic | Details |
| GLPG-3667 | GLPG-3667 | Phase 2 Clinical | Galapagos Nv | Dermatomyositis; Lupus Erythematosus, Systemic; Plaque psoriasis | Details |
| OST-122 | OST-122 | Phase 2 Clinical | Oncostellae Sl | Colitis, Ulcerative; Colorectal Neoplasms; Fibrosis; Inflammatory Bowel Diseases | Details |
| Ropsacitinib | PF-06826647 | Phase 2 Clinical | Pfizer Inc | Colitis, Ulcerative; Hidradenitis Suppurativa; Plaque psoriasis; Psoriasis | Details |
| Lomedeucitinib | BMS-986322 | Phase 2 Clinical | Bristol-Myers Squibb Company | Central Nervous System Diseases; Multiple Sclerosis; Psoriasis | Details |
| UA-021 | UA-021 | Phase 2 Clinical | Yousen Jianheng Biomedical (Shanghai) Co Ltd | Colitis, Ulcerative; Crohn Disease; Lupus Nephritis; Psoriasis | Details |
| TQH-3906 | TQH-3906; TQH3906 | Phase 2 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Inflammatory Bowel Diseases; Lupus Erythematosus, Systemic; Plaque psoriasis; Psoriasis | Details |
| CS-32582 | CS-32582; CS32582 | Phase 2 Clinical | Shenzhen Chipscreen Biosciences Co Ltd | Autoimmune Diseases; Plaque psoriasis; Psoriasis | Details |
| TDM-180935 | TDM-180935 | Phase 2 Clinical | Jiaxing TechnoDerma Medicines Inc | Dermatitis, Atopic | Details |
| Cenacitinib | VTX-958 | Phase 2 Clinical | Ventyx Biosciences Inc | Arthritis, Psoriatic; Crohn Disease; Plaque psoriasis; Psoriasis | Details |
| AC-201 | AC-201 | Phase 2 Clinical | Accro Bioscience (Suzhou) Co Ltd | Lupus Erythematosus, Systemic; Plaque psoriasis; Psoriasis; Uveitis | Details |
| ABBV-712 | ABBV-712 | Phase 1 Clinical | Abbvie Inc | Psoriasis | Details |
| GLPG-3121 | GLPG-3121 | Phase 1 Clinical | Galapagos Nv | Details | |
| A-005 | Phase 1 Clinical | Alumis Inc | Central Nervous System Infections; Encephalomyelitis; Multiple Sclerosis; Nerve Degeneration; Parkinson Disease | Details | |
| TYK2 inhibitor (BMS) | Phase 1 Clinical | Bristol-Myers Squibb Company | Autoimmune Diseases | Details | |
| ZE74-0022 | ZE74-0022 | Phase 1 Clinical | Barinthus Biotherapeutics PLC | Diabetes Mellitus, Type 1 | Details |
| NEU-627 | NEU-627 | Phase 1 Clinical | Neuron23 Inc | Multiple Sclerosis; Neuritis | Details |
| NEU-111 | NEU-111 | Phase 1 Clinical | Neuron23 Inc | Details | |
| ZG-002(Shanghai Zhi Gen) | Phase 1 Clinical | Shanghai Zhi Gen Pharmaceutical Technology Co Ltd | Plaque psoriasis | Details | |
| A-005(Alumis) | A-005(Alumis) | Phase 1 Clinical | Alumis Inc | Multiple Sclerosis; Nerve Degeneration; Neuritis; Parkinson Disease | Details |
| WD-910 | WD-910 | Phase 1 Clinical | Ningbo Wenda Pharma | Dementia; Multiple Sclerosis | Details |
| SUDO-286 | SUDO-286 | Phase 1 Clinical | Sudo Biosciences Inc | Psoriasis; Skin Diseases | Details |
| SUDO-550 | SUDO-550 | Phase 1 Clinical | Sudo Biosciences Inc | Brain Diseases; Multiple Sclerosis; Neurodegenerative Diseases | Details |
| FZ007-119 | FZ007; FZ-007 | Phase 1 Clinical | Guangzhou Fermion Technology Co Ltd | Autoimmune Diseases; Dermatitis, Atopic; Psoriasis | Details |
| ARTS-011 | ARTS-011; ARTS011 | Phase 1 Clinical | Anrui Biomedical Technology (Guangzhou) Co Ltd | Plaque psoriasis | Details |
| LNK-01006 | LNK-01006 | Phase 1 Clinical | Lynk Pharmaceutical (Hangzhou) Co Ltd | Neuroinflammatory Diseases; Solid tumours | Details |
| QY-211 | QY211; QY-211 | Phase 1 Clinical | E-nitiate Biopharmaceuticals (Hangzhou) Co Ltd | Dermatitis, Atopic; Eczema; Vitiligo | Details |
| MAX-40070 | MAX-40070; MAX-3 | Phase 1 Clinical | MaxiNovel Pharmaceuticals Co Ltd | Alopecia Areata | Details |
| BGB-23339 | BGB-23339 | Phase 1 Clinical | BeOne Medicines Ltd | Autoimmune Diseases; Plaque psoriasis | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Peficitinib | ASP-015K; JNJ-54781532 | Approved | Astellas Pharma Inc | Smyraf, 施觅福 | Japan | Arthritis, Rheumatoid | Astellas Pharma Inc | 2019-03-29 | Arthritis, Rheumatoid; Colitis, Ulcerative; Psoriasis | Details |
| Gecacitinib Hydrochloride | ZG-0128; ZG-0163 | Approved | Suzhou Zelgen Biosciences Co Ltd | 泽普平 | Mainland China | Primary Myelofibrosis | Suzhou Zelgen Biopharmaceuticals Co Ltd | 2025-05-27 | Alopecia Areata; Carcinoma, Non-Small-Cell Lung; Coronavirus Disease 2019 (COVID-19); Dermatitis, Atopic; Graft vs Host Disease; Hepatic Insufficiency; Idiopathic Pulmonary Fibrosis; Lupus Erythematosus, Systemic; Lymphoma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Plaque psoriasis; Pneumonia; Polycythemia Vera; Primary Myelofibrosis; Solid tumours; Spondylitis, Ankylosing; Thrombocythemia, Essential; Vitiligo | Details |
| Deucravacitinib | BMS-986165; BMS-986165-01 | Approved | Bristol-Myers Squibb Company | Sotyktu, 颂狄多 | United States | Plaque psoriasis | Bristol-Myers Squibb Company | 2022-09-09 | Alopecia Areata; Arthritis, Juvenile; Arthritis, Psoriatic; Autoimmune Diseases; Colitis, Ulcerative; Crohn Disease; Dermatomyositis; Granuloma Annulare; Hidradenitis Suppurativa; Inflammation; Inflammatory Bowel Diseases; Lichen Planus; Liver Dysfunction; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Lupus Nephritis; Lupus Vulgaris; Myositis; Plaque psoriasis; Psoriasis; Pyoderma Gangrenosum; Renal Insufficiency; Rosacea; Sarcoidosis; Sjogren's Syndrome; Sjogren-Larsson Syndrome; Vitiligo | Details |
| Rovadicitinib | TQ-05105; CT-1995; TQ05105 | Approved | Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd | 安煦, Anxu | Mainland China | Primary Myelofibrosis | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2026-02-25 | Graft vs Host Disease; Lymphohistiocytosis, Hemophagocytic; Myeloproliferative Disorders; Primary Myelofibrosis | Details |